A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia

This study has been completed.
Celgene Corporation
Information provided by (Responsible Party):
University of Utah
ClinicalTrials.gov Identifier:
First received: April 29, 2011
Last updated: September 28, 2015
Last verified: September 2015

The primary objective of this study is:

Response to treatment will be evaluated according to the revised International Working Group (IWG) categories natural history, hematologic improvement and cytogenetic response1;2. The primary objective is:

To determine the rate of complete hematologic response and hematologic improvement (according to IWG 2006 criteria) in CMML patients treated with 5-azacitidine.

Condition Intervention Phase
Chronic Myelomonocytic Leukemia
Drug: 5-Azacitidine
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of the Efficacy, Safety and Determinants of Response to 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia (CMML)

Resource links provided by NLM:

Further study details as provided by University of Utah:

Primary Outcome Measures:
  • To Determine the Rate of Complete Hematologic Response (According to IWG 2006 Criteria) in CMML Patients Treated With 5-azacitidine. [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: April 2011
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: All patients
All participants enrolled.
Drug: 5-Azacitidine

Administered on Days 1-7 of each Cycle.

Subcutaneous administration:

To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.

The 5-azacitidine suspension is administered subcutaneously.

Intravenous Administration:

5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes.

Other Name: Vidaza®

Detailed Description:

In this study, eligible patients with a confirmed diagnosis of CMML will be treated with 5-azacitidine to determine the rates of complete hematologic response, hematologic improvement, complete and partial cytogenetic response, and overall and progression free survival.

To develop biomarkers associated with response and gain insights into the mechanisms that determine response, gene expression profiling, genome-wide SNP array analysis, microRNA analysis, and DNA methylation analysis will be performed prior to therapy and at defined time points during the study. Phosphoproteomics profiling may be included in the analysis.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Diagnosis of CMML as defined by the WHO criteria

    1. Persistent peripheral blood monocytosis of more than 1 x 109/L for at least 3 months and
    2. No Philadelphia chromosome or BCR-ABL fusion gene and
    3. Less than 20% blasts in the blood or bone marrow and
    4. Dysplasia in one or more of the myeloid lineages* * In the absence of dysplasia in one or more of the myeloid lineages, the diagnosis of CMML can still be made if a) - c) are met AND an acquired clonal chromosomal abnormality is present in the bone marrow cells, the monocytosis has been present for more than 3months AND all other causes of monocytosis have been ruled out.
  2. Age of 18 years or older. Both men and women and members of all races and ethnic groups will be included.
  3. ECOG performance status <3
  4. Adequate organ function defined as:

    1. Total bilirubin <2.5 x upper limit of normal (ULN)
    2. Direct bilirubin <2 x ULN
    3. Creatinine <2 mg/dL
    4. ALT and AST <2.5 x ULN
  5. Ability to understand and the willingness to sign a written informed consent document
  6. Willingness to use adequate contraception for the duration of the study

Exclusion Criteria:

  1. Progression to acute myeloid leukemia (defined by at least 20% blasts in the blood or bone marrow). In the unlikely event that progression to acute leukemia is demonstrated in the "screening" bone marrow biopsy, it is at the discretion of the investigator to enroll the patient after adequate discussion of the findings and alternative therapies. Enrollment of such a patient must be reported to the HCI PI.
  2. Presence of activating mutations of the platelet derived growth factor receptors alpha or beta, which would suggest likely benefit from imatinib treatment (these mutations will usually be obvious from karyotyping and fluorescence in situ hybridization studies)
  3. Known or suspected hypersensitivity to 5-azacitidine or mannitol
  4. Clinically significant heart disease (New York Heart Association Class III or IV) or other serious intercurrent illnesses or psychiatric illness/social situations that would limit compliance with study requirements
  5. Major surgery within 28 days before registration (exception: central venous line placement), or lack of full recovery from prior major surgery
  6. Prior therapy with a hypomethylating agent
  7. Cytotoxic chemotherapy less than 2 weeks prior to starting study medication (exception: hydroxyurea and/or anagrelide)
  8. Erythropoietin or darbepoietin, G-CSF, GM-CSF, thalidomide or lenalidomide less than 2 weeks from day 1 of cycle 1
  9. Concomitant cytotoxic chemotherapy (exception: hydroxyurea for up to 1 week per cycle)
  10. Concomitant therapy with other investigational agents
  11. Other active malignancies except basal cell carcinoma of the skin and carcinoma in situ of the cervix.
  12. Pregnancy or breastfeeding (possible risk to the fetus or infant)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01350947

United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
United States, Oregon
Oregon Health and Science University
Portland, Oregon, United States, 97239
United States, Utah
University of Utah
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
University of Utah
Celgene Corporation
Principal Investigator: Michael Deininger, MD University of Utah
  More Information

Responsible Party: University of Utah
ClinicalTrials.gov Identifier: NCT01350947     History of Changes
Other Study ID Numbers: HCI47081 
Study First Received: April 29, 2011
Results First Received: September 28, 2015
Last Updated: September 28, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by University of Utah:
Chronic Myelomonocytic Leukemia

Additional relevant MeSH terms:
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Bone Marrow Diseases
Hematologic Diseases
Leukemia, Myeloid
Myelodysplastic-Myeloproliferative Diseases
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 22, 2016